Escherichia coli Nissle 1917 (Nissle 1917) is a promising candidate with probiotic properties. Here, we used Nissle 1917 to develop a metabolic strategy to produce 5-aminolevulin … Bacterial vectors can be engineered to generate microscopic living therapeutics to produce and deliver anticancer agents.
Our results show a robust engineered probiotic that produces 73.4 ± 47.2 nmol and 149 ± 123.6 nmol of ILA per gram of fecal and cecal matter, respectively, three days after colonization in a mouse model. In addition, hereby is reported an engineered-probiotic-related increase of ILA in the systemic circulation of the treated mice.
Of note, the probiotic strain E. coli Nissle 1917 (EcN) 112 has been safely used for nearly 100 years as the active pharmaceutical ingredient in multiple licensed medicinal products and the anti
wRzR.